NeoGenomics Inc. ( (NEO) ) has released its Q1 earnings. Here is a breakdown of the information NeoGenomics Inc. presented to its investors.
NeoGenomics, Inc. is a leading cancer diagnostics company specializing in cancer genetics testing and information services, offering a comprehensive oncology-focused testing menu to various healthcare professionals and organizations. In its first-quarter earnings report for 2025, NeoGenomics reported an 8% increase in consolidated revenue, reaching $168 million, alongside a 4% reduction in net loss to $26 million. The company also achieved a significant 102% increase in adjusted EBITDA to $7 million, reflecting improved operational efficiency and strategic growth initiatives.
Key financial highlights include a 12% rise in gross profit to $73 million, driven by increased revenue and strategic reimbursement initiatives, despite higher compensation and supply expenses. Operating expenses rose by 5% due to increased compensation and technology costs, although these were partially offset by reduced restructuring and facility costs. The company’s cash and cash equivalents stood at $358 million at the end of the quarter.
NeoGenomics revised its full-year 2025 guidance, projecting a 13% to 15% increase in consolidated revenue, partially due to the acquisition of Pathline, LLC. The company anticipates continued growth through new product launches and enhanced customer experiences, supported by its robust sales force.
Looking ahead, NeoGenomics remains focused on accelerating growth and improving patient care through its expanding portfolio and strategic initiatives, as indicated by the management’s optimistic outlook for the remainder of 2025.